Primary hyperaldosteronism

Annals of Clinical Biochemistry

Volumn 40, Issue 5, 2003, Pages 439-452

  Nadar, Sunil ^a   Lip, Gregory Y H ^a   Beevers, D Gareth ^a  

^a UNIVERSITY DEPARTMENT OF MEDICINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

18 HYDROXYCORTICOSTERONE; ALDOSTERONE; ALDOSTERONE ANTAGONIST; ALPHA ADRENERGIC RECEPTOR BLOCKING AGENT; AMILORIDE; ANGIOTENSIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ASPARTATE POTASSIUM; BENZTHIAZIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; CAPTOPRIL; DEXAMETHASONE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; DOXAZOSIN; FLUDROCORTISONE; FRUCTOSE; FUROSEMIDE; HYDROCORTISONE; KETOCONAZOLE; MINOXIDIL; MITOTANE; POTASSIUM; POTASSIUM DERIVATIVE; RENIN; SODIUM CHLORIDE; SPIRONOLACTONE; UNCLASSIFIED DRUG;

ADRENAL SCINTISCANNING; ADRENAL TUMOR; ADRENALECTOMY; ALDOSTERONE BLOOD LEVEL; ALDOSTERONE RELEASE; BODY POSTURE; CIRCADIAN RHYTHM; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONGENITAL ADRENAL HYPERPLASIA; CUSHING DISEASE; DIAGNOSTIC ACCURACY; DIAGNOSTIC ERROR; DIAGNOSTIC PROCEDURE; DIAGNOSTIC TEST; DIAGNOSTIC VALUE; DISEASE MARKER; DRUG EFFECT; ENDOCRINE FUNCTION TEST; FATIGUE; GYNECOMASTIA; HUMAN; HYDROCORTISONE BLOOD LEVEL; HYPERKALEMIA; HYPERTENSION; IMPOTENCE; INFUSION; LABORATORY DIAGNOSIS; LAPAROSCOPIC SURGERY; LIDDLE SYNDROME; NAUSEA; NONHUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOPHYSIOLOGY; PLASMA RENIN ACTIVITY; POTASSIUM BLOOD LEVEL; POTASSIUM URINE LEVEL; PREVALENCE; PRIMARY HYPERALDOSTERONISM; PRIORITY JOURNAL; RADIODIAGNOSIS; REVIEW; SCREENING TEST; SURGICAL TECHNIQUE; TREATMENT OUTCOME; WATER IMMERSION;

HUMANS; HYPERALDOSTERONISM;

EID: 0141518163     PISSN: 00045632     EISSN: None     Source Type: Journal    
DOI: 10.1258/000456303322326362     Document Type: Review

References (104)

1. Holland OB. Primary hyperaldosteronism. Semin Nephrol 1995; 15: 116-25
2. Connell JM. Is there an epidemic of primary hyperaldosteronism. J Hum Hypertens 2002; 16: 151-2
3. Gordon RD, Stowasser M, Tunny TJ, Klemm SA, Rutherford JC. High incidence of primary hyperaldosteronism in 199 patients referred with hypertension. Clin Exp Pharmacol Physiol 1994; 21: 315-8
4. Lim PO, Dow E, Brennan G, Jung RT, MacDonald TM. High prevalence of primary hyperaldosteronism in the Tayside hypertension clinic population. J Hum Hypertens 2000; 14: 311-5
5. Sherwin RP, Conn JW. Present status of pathology of adrenal gland in hypertension. Am J Surg 1964; 107: 136-43
6. Terzolo M, Ali A, Osella G, Mazza E. Prevalence of adrenal carcinoma among incidentally discovered adrenal masses. A retrospective study from 1989 to 1994. Gruppo Piemontese Incidentalomi Surrenalici. Arch Surg 1997; 132: 914-9
7. Ferriss JB, Beevers DG, Brown JJ, Davies DL, Fraser R, Lever AF, et al. Clinical, biochemical and pathological features of low-renin ('primary') hyperaldosteronism. Am Heart J 1978; 95: 375-88
8. Salomon MI, Tchertkoff V. Incidence and role of adrenocortical tumors in hypertension. Geriatrics 1968; 23: 184
9. Russell RP, Masi AT, Ritcher ED. Adrenal cortical adenomas and hypertension. Medicine 1972; 51: 211-25
10. Tucker RM, Labarthe DR. Frequency of surgical treatment for hypertension in adults at the Mayo Clinic from 1973 though to 1975. Mayo Clin Proc 1977; 52: 549-55
11. Anderson GH, Blakeman N, Streeten DHP. The effect of age on prevalence of secondary forms of hypertension in 4429 consecutively referred patients. J Hypertens 1994; 12: 609-15
12. Loh KC, Koay ES, Khaw MC, Emmanuel SC, Young WF Jr. Prevalence of pdmary hyperaldosteronism among Asian hypertensive patients in Singapore. J Clin Endocrinol Metab 2000; 85: 2854-9
13. Rayner BL, Opie LH, Davidson JS. The aldosterone/renin ratio as a screening test for primary hyperaldosteronism. S Afr Med J 2000; 90: 394-400
14. Donoghue M, Hsieh F, Baronas E, Godbout K, Gosselin M, Stagliano N, et al. A novel angiotensin-converting enzyme-related carboxypeptidase (ACE2) converts angiotensin I to angiotensin 1-9. Circ Res 2000; 87: E1-E9
15. Tipnis SR, Hooper NM, Hyde R, Karran E, Christie G, Turner AJ. A human homolog of angiotensin-converting enzyme. Cloning and functional expression as a captopril-insensitive carboxypeptidase. J Biol Chem 2000; 275: 33238-43
16. Crackower MA, Sarao R, Oudit GY, Yagil C, Kozieradzki I, Scanga SE, et al. Angiotensin-converting enzyme 2 is an essential regulator of heart function. Nature 2002; 417: 822-8
17. Mulrow PJ. Renin-angiotensin system in the adrenal. Horm Metab Res 1998; 30: 346-9
18. Mulrow PJ. Angiotensin II and aldosterone regulation. Regul Pept 1999; 80: 27-32
19. White PC. Disorders of aldosterone biosynthesis and action. N Engl J Med 1994; 331: 250-8
20. Quinn SJ, Williams GH. Regulation of aldosterone secretion. Annu Rev Physiol 1988; 50: 409-26
21. Irony I, Kater CE, Biglieri EG, Shackleton CHL. Correctable subsets of primary hyperaldosteronism. Primary adrenal hyperplasia and renin responsive adenoma. Am J Hypertens 1990; 3: 576-82
22. Ulick S, Blumenfeld JD, Atlas SA. The unique steroidogenesis of the aldosteronoma in the differential diagnosis of primary hyperaldosteronism. J Clin Endocrinol Metab 1993; 76: 873-8
23. Kem DC, Weinberger MH, Higgins JR. Plasma aldosterone response to ACTH in primary hyperaidosteronism and in patients with low renin hypertension. J Clin Endocrinol Metab 1978; 46: 552-60
24. Wisgerhof M, Brown RD. Increased adrenal sensitivity to angiotensin II in low renin essential hypertension. J Clin Invest 1978; 61: 1456-62
25. Blumenfeld JD, Sealey JE, Schlussel Y, Vaughan ED, Sos TA, Atlas SA, et al. Diagnosis and treatment of primary hyperaldosteronism. Ann Intern Med 1994; 121: 877-85
26. Weinberger MH, Grim CE, Hollifield JW. Primary hyperaldosteronism. Diagnosis, localization and treatment. Ann Intern Med 1979; 67: 403-13
27. McAreavey D, Murray GD, Lever AF, Robertson JI. Similarity of idiopathic hyperaldosteronism and essential hypertension. A statistical comparison. Hypertension 1983; 5: 116-21
28. Brown JJ, Lever AF, Robertson JI, Beevers DG, Cumming AM, Davies DL, et al. Are idiopathic hyperaldosteronism and low-renin hypertension variants of essential hypertension? Ann Clin Biochem 1979; 16: 380-8
29. Haenel LC, Hermayer KL. A case of unilateral adrenal hyperplasia: the diagnostic dilemma of hyperaldosteronism. Endocr Pract 2000; 6: 153-8
30. Omura M, Sasano H, Fujiwara T, Yamaguchi K, Nishikawa T. Unique cases of unilateral hyperaldosteronemia due to multiple adrenocortical micronodules, which can only be detected by selective adrenal venous sampling. Metabolism 2002; 51: 350-5
31. Mansoor GA, Malchoff CD, Arici MH, Karimeddini MK, Whalen GF. Unilateral adrenal hyperplasia causing primary hyperaldosteronism: limitations of I-131 norcholesterol scanning. Am J Hypertens 2002; 15: 459-64
32. Arteaga E, Biglieri EG, Kater CE. Aldosterone-producing adrenocortical carcinoma. Ann Intern Med 1984; 101: 316-21
33. Sutherland DJ, Ruse JL, Laidlaw JC. Hypertension, increased aldosterone secretion and low plasma renin activity relieved by dexamethasone. Can Med Assoc J 1966; 95: 1109-19
34. Lifton RP, Dluhy RG, Powers M. A chimaeric 11 β -hydroxylase/aldosterone synthase gene causes glucocorticoid remediable hyperaldosteronism and human hypertension. Nature 1992; 355: 262-5
35. Pascoe L, Curnow KM, Slutsker L. Glucocorticoid suppressible hyperaldosteronism results from hybrid genes created by unequal crossovers between CYP11B1 and CYP11B2. Proc Natl Acad Sci USA 1992; 89: 8327-31
36. Conn JW. Primary hyperaldosteronism, a new clinical syndrome. J Lab Clin Med 1955; 45: 3-17
37. Zarifis J, Lip GY, Leatherdale B, Beevers G. Malignant hypertension in association with primary hyperaldosteronism. Blood Press 1996; 5: 250-4
38. Lim PO, Jung RT, MacDonald TM. Is aldosterone the missing link in refractory hypertension? Aldosterone to renin ratio as a marker of inappropdate aldosterone activity. J Hum Hypertens 2002; 16: 153-8
39. Padfield PL. Primary hyperaldosteronism, a common entity? the myth persists. J Hum Hypertens 2002; 16: 159-62
40. Rayner BL, Myers JE, Opie LH, Trinder YA, Davidson JS. Screening for primary hyperaldosteronism: normal ranges for aldosterone and renin in three South African population groups. S Afr Med J 2001; 91: 594-9
41. Kapoor M, Chan GZ. Fluid and electrolyte abnormalities. Crit Care Clin 2001; 17: 503-29
42. Bartholow C, Whittier FC, Rutecki GW. Hypokalaemia and metabolic alkalosis: algorithms for combined clinical problem-solving. Compr Ther 2000; 26: 114-20
43. Bravo EL, Tarazi RC, Dustan HP, Fouad FM, Textur SC, Gifford RW, et al. The changing clinical spectrum of primary hyperaldosteronism. Am J Med 1983; 74: 641-64
44. Laragh JH. Renin profiling for diagnosis, risk assessment and treatment of hypertension. Kidney Int 1993; 44: 1163-75
45. Vallotton MB. Primary hyperaldosteronism. Part I. Diagnosis of primary hyperaldosteronism. Clin Endocrinol 1996; 45: 47-52
46. Letizia C, De Ciocchis A, Cerci S, Coassin S, Fisher H, Tarsitani P, et al. Amlodipine in ambulatory hypertensive patients: humoral and haemodynamic effects. Int J Clin Pharmacol Res 1993; 13: 151-9
47. Buckley JW, Hedner T, Masotto C, Posvar E, Negro-Villar A, Cubeddu LX. Comparative effects of verapamil and volume overload on atrial natriuretic factors and the renin-angiotensin aldosterone-vasopressin system. J Clin Pharmacol 1992; 32: 1120-7
48. Waldhausl A, Lewandowski JA. Measurement of plasma renin concentration using endogenous substrate and radioimmunoassay. Eur J Clin Invest 1973; 3: 1-9
49. Zuo WM, Pratt RE, Heusser CH, Bews JPA, deGaspara MM, Dzau VJ. Characterization of a monodonal antibody specific for active renin. Hypertension 1992; 19: 249-54
50. Derkx FHM, deBruin RJA, van Gool JMG, van den Hoek MJ, Berendonk CCM, Rosmalen F. Clinical validation of renin monoclonal antibody-based sandwich assays of renin and prorenin, and use of renin inhibitor to enhance prorenin immunoreactivity. Clin Chem 1996; 42: 1051-63
51. Sealey JE, Trenkwalder P, Gahnem F, Catanzaro D, Laragh JH. Plasma renin methodology: inadequate sensitivity and accuracy of direct renin assay for clinical applications compared with traditional enzymatic plasma renin activity assay. J Hypertens 1995; 13: 27-30
52. Kem DC, Weinberger MH, Gomez-Sanchez C, Kramer NJ, Lerman R, Furuyama S, et al. Circadian rhythm of plasma aldosterone concentration in patients with primary hyperaldosteronism. J Clin Invest 1973; 52: 2272-7
53. Nomura K, Toraya S, Horiba N, Ujihara M, Aiba M, Demura H. Plasma aldosterone response to upright posture and angiotensin II infusion in aldosterone-producing adenoma. J Clin Endocrinol Metab 1992; 75: 323-7
54. Mckenna TJ, Sequeira SJ, Heffernan A, Chambers J, Cunningham S. Diagnosis under random conditions of all disorders of the renin angiotensin aldosterone axis, including primary hyperaldosteronism. J Clin Endocrinol Metab 1991; 73: 952-7
55. Cartledge S, Lawson N. Aldosterone and renin measurements. Ann Clin Biochem 2000; 37: 262-78
56. Hiramatsu K, Yamada T, Yukimura Y. A screening test to identify aldosterone-producing adenoma by measuring plasma renin activity: results in hypertensive patients. Arch Intern Med 1981; 141: 1589-93
57. Hamlet SM, Tunny TJ, Woodland E, Gordon RD. Is aldosterone/renin ratio useful to screen a hypertensive population for primary hyperaldosteronism? Clin Exp Pharmacol Physiol 1985; 12: 249-52
58. Fishman LM, Kuchel O, Liddle GW, Michelakis AM, Gordon RD, Chick WT. Incidence of primary hyperaldosteronism uncomplicated 'essential' hypertension. A prospective study with elevated aldosterone secretion and suppressed plasma renin activity used as diagnostic criteria. JAMA 1968; 205: 497-502
59. Gordon RD, Fishman LM, Liddle GW. Plasma renin activity and aldosterone secretion in a pregnant woman with primary hyperaldosteronism. J Clin Endocrinol Metab 1967; 27: 385-8
60. Hamlet SM, Tunny TJ, Woodland E, Gordon RD. Is aldosterone/renin ratio useful to screen a hypertensive population for primary hyperaldosteronism. Clin Exp Pharmacol Physiol 1985; 12: 249-52
61. Gallay BJ, Abroad S, Xu L, Toivola B, Davidson RC. Screening for primary hyperaldosteronism without discontinuing hypertensive medications: plasma aldosterone-renin ratio. Am J Kidney Dis 2001; 37: 699-705
62. Castro OL, Yu X, Kem DC. Diagnostic value of the post-captopril test in primary hyperaldosteronism. Hypertension 2002; 39: 935-8
63. Trenkel S, Seifarth C, Schobel H, Hahn EG, Hensen J. Ratio of serum aldosterone to plasma renin concentration in essential hypertension and primary hyperaldosteronism. Exp Clin Endocrinol Diabetes 2002; 110: 80-5
64. Montori VM, Young WF Jr. Use of plasma aldosterone concentration-to-plasma renin activity ratio as a screening test for primary hyperaldosteronism. A systematic review of the literature. Endocrinol Metab Clin North Am 2002; 31: 619-32
65. Kaplan NM. Cautions over the current epidemic of primary hyperaldosteronism. Lancet 2000; 357: 953-4
66. Fraser R, Lever AE Brown JJ, Robertson JI. Cautions over idiopathic hyperaldosteronism. Lancet 2001; 358: 332
67. Kaplan NM. hypokalaemia in the hypertensive patient with observations on the incidence of primary hyperaldosteronism. Ann Intern Med 1967; 66: 1079-90
68. Holland OB, Brown H, Kuhnert L, Fairchild C, Risk M, Gomez-Sanchez C. Further evaluation of saline infusion for the diagnosis of primary hyperaldosteronism. Hypertension 1984; 6: 717-23
69. Streeten DH, Tomycz N, Anderson GH. Reliability of screening methods for the diagnosis of primary hyperaldosteronism. Am J Med 1979; 67: 403-13
70. Gordon RD, Stowasser M, Klemm SA, Tunny TJ. Primary hyperaldosteronism and other forms of mineralocorticoid hypertension. In: Swales JD, ed. Textbook of Hypertension. London: Blackwell Scientific, 1994: 865-92
71. Lyons DF, Kem DC Brown RD, Hanson CS. Single dose captopril as a diagnostic test for primary hyperaldosteronism. J Clin Endocnnol Metab 1983; 57: 892-6
72. Agharazii M, Douville P, Grose JH, Lebel M. Captopril suppression versus salt loading in confirming primary hyperaldosteronism. Hypertension 2001; 37: 1440-3
73. Racine MC, Douville P, Lebel M. Functional tests for primary hyperaldosteronism: value of captopril suppression. Curr Hypertens Rep 2002; 4: 245-9
74. Zavagli G, Ricci G, Gilli G, Antolini G, Castaldi G. An easy diagnostic approach to primary hyperaldosteronism. Steroids 1999; 64: 296-300
75. Rossi GP, Rossi E, Pavan E, Rosati N, Zecchel R, Semplicini A, et al. Screening for primary hyperaldosteronism with a logistic multivariate discriminant analysis. Clin Endocrinol 1998; 49: 713-23
76. Coruzzi P, Musiari L, Biggi A, Carra N, Panzali AF, Novarini A. A new diagnostic test for primary hyperaldosteronism. Am J Hypertens 1991; 4: 694-9
77. Bravo EL. Primary hyperaldosteronism: new approaches to diagnosis and management. Cleve Clin J Med 1993; 60: 379-86
78. Hambling C, Jung RT, Browning MC, Gunn A, Anderson JM. Primary hyperaldosteronism: evaluation of procedures for diagnosis and localization. QJM 1993; 86: 383-92
79. Ganguly A, Melada GA, Luetscher JA, Dowdy AJ. Control of plasma aldosterone in primary hyperaldosteronism: distinction between adenoma and hyperplasia. J Clin Endocrinol 1973; 37: 765-75
80. Vetter H, Berger M, Armbruster H, Siegenthaler W. Episodic secretion of aldosterone in primary hyperaldosteronism: relationship to cortisol. Clin Endocrinol 1974; 45: 47-52
81. Biglieri EG, Irony I, Kater CE. Identification and implications of new types of mineralocorticoid hypertension. J Steroid Biochem 1989; 32: 199-204
82. Biglieri EG, Schambelan M, Hirai J, Chang B. The significance of elevated levels of plasma 18 hydroxycorticosterone in patients with primary hyperaldosteronism. J Clin Endocrinol Metab 1979; 49: 87-91
83. Ulick S, Chu MD. Hypersecretion of a new corticosteroid 18 hydroxycortisol in two types of adrenal cortical hypertension. Clin Exp Hypertens 1982; 4: 1771-7
84. Fraser R, Connell MC, Budd PS, Corrie BET. The origin and significance of 18 hydroxycortisol: studies in hyperaldosteronism and in bovine adrenocortical cells in vitro. J Steroid Biochem Mol Biol 1991; 39: 839-50
85. Radin DR, Manoogian C, Nadler JL. Diagnosis of primary hyperaldosteronism: importance of correlating CT findings with endocrinologic studies. Am J Roentgenol 1992; 158: 553-7
86. Arnaldi G, Masini AM, Giacchetti G, Taccaliti A, Faloia E, Mantero F. Adrenal incidentaloma. Braz J Med Biol Res 2000; 3: 1177-89
87. McAlister FA, Lewanczuk RZ. Primary hyperaldosteronism and adrenal incidentaloma: an argument for physiologic testing before adrenalectomy. Can J Surg 1998; 41: 299-305
88. Rossi GP, Chiesura-Corona M, Tregnaghi A, Zanin L, Perale R, Soattin S, et al. Imaging of aldosterone-secreting adenomas: a prospective comparison of computed tomography and magnetic resonance imaging in 27 patients with suspected primary hyperaldosteronism. J Hum Hypertens 1993; 7: 357-63
89. Sohaib SA, Peppercorn PD, Allan C, Monson JP, Grossman AB, Besser GM, et al. Primary hyperaldosteronism (Conn syndrome): MR imaging findings. Radiology 2000; 214: 527-31
90. Korobkin M, Francis IR. Adrenal imaging. Semin Ultrasound CT MR 1995; 16: 317-30
91. Gleason PE, Weinberger MH, Pratt JH, Bihrle R, Dugan J, Eller D, et al. Evaluation of diagnostic tests in the differential diagnosis of primary hyperaldosteronism: unilateral adenoma versus bilateral micronodular hyperplasia. J Urol 1993; 150: 1365-8
92. Wu KD, Liao TS, Chen YM, Lai MK, Chen SJ, Su CT, et al. Preoperative diagnosis and localization of aldosterone-producing adenoma by adrenal venous sampling after administration of metoclopramide. J Formos Med Assoc 2001; 100: 598-603
93. Rossi GP, Sacchetto A, Chiesura-Corona M, De Toni R, Gallina M, Feltrin GP, et al. Identification of the etiology of primary hyperaldosteronism with adrenal vein sampling in patients with equivocal computed tomography and magnetic resonance findings: results in 104 consecutive cases. J Clin Endocrinol Metab 2001; 86: 1083-90
94. Liddle GW, Bledsoe T, Coppage WS. A familial disorder simulating primary hyperaldosteronism but with negligible aldosterone secretion. Trans Assoc Am Physicians 1963; 76: 199-213
95. Sayer JA, Pearce SH. Diagnosis and clinical biochemistry of inherited tubulopathies. Ann Clin Biochem 2001; 38: 459-70
96. Brunt LM, Moley JF, Doherty GM, Lairmore TC, DeBenedetti MK, Quasebarth MA. Outcomes analysis in patients undergoing laparoscopic adrenalectomy for hormonally active adrenal tumors. Surgery 2001; 130: 629-34
97. Takeda M, Go H, Imai T, Nishiyama T, Morishita H. Laparoscopic adrenalectomy for primary hyperaldosteronism: report of initial ten cases. Surgery 1994; 115: 621-5
98. Guazzoni G, Montorsi R, Bergamaschi F. Effectiveness and safety of laparoscopic adrenalectomy. J Urol 1994; 152: 1375-8
99. Weigel RJ, Wells SA, Gunnells JC, Leight GS. Surgical treatment of primary hyperaldosteronism. Ann Surg 1994; 219: 347-52
100. Gadallah MF, Kayyas Y, Boules F. Reversible suppression of the renin-aldosterone axis after unilateral adrenalectomy for adrenal adenoma. Am J Kidney Dis 1998; 32: 160-3
101. Inoue H, Nakajo M, Miyazono N, Nishida H, Ueno K, Holotate H. Transcatheter arterial ablation of aldosteronomas with high concentration ethanol: preliminary and long-term results. Am J Roentgenol 1997; 168: 1241-5
102. Mantero F, Armanini D, Boscaro M, Carpene G, Fallo F. Steroids and hypertension. J Steroid Biochem Mol Biol 1991; 40: 35-44
103. Young WF Jr, Hogan MJ. Renin-independent hypermineralocorticoidism. Trends Endocrinol Metab 1994; 5: 97-106
104. Harper R, Ferrett CG, McKnight JA, Mcllrath EM, Russell CF, Sheridan B, et al. Accuracy of CT scanning and adrenal vein sampling in the pre-operative localization of aldosterone-secreting adrenal adenomas. QJM 1999; 92: 643-50